Logo image of PLX

PROTALIX BIOTHERAPEUTICS INC (PLX) Stock Fundamental Analysis

NYSEARCA:PLX - NYSE Arca - US74365A3095 - Common Stock - Currency: USD

2.39  -0.04 (-1.65%)

After market: 2.39 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to PLX. PLX was compared to 572 industry peers in the Biotechnology industry. While PLX seems to be doing ok healthwise, there are quite some concerns on its profitability. PLX is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year PLX has reported negative net income.
PLX had a positive operating cash flow in the past year.
PLX had negative earnings in 4 of the past 5 years.
In the past 5 years PLX always reported negative operating cash flow.
PLX Yearly Net Income VS EBIT VS OCF VS FCFPLX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M

1.2 Ratios

With an excellent Return On Assets value of -15.60%, PLX belongs to the best of the industry, outperforming 82.42% of the companies in the same industry.
Looking at the Return On Equity, with a value of -29.61%, PLX is in the better half of the industry, outperforming 78.69% of the companies in the same industry.
Industry RankSector Rank
ROA -15.6%
ROE -29.61%
ROIC N/A
ROA(3y)-18.11%
ROA(5y)-20.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PLX Yearly ROA, ROE, ROICPLX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 400

1.3 Margins

PLX's Operating Margin has improved in the last couple of years.
PLX has a better Gross Margin (35.86%) than 76.02% of its industry peers.
PLX's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for PLX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 35.86%
OM growth 3Y54.76%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.76%
GM growth 5Y-2.28%
PLX Yearly Profit, Operating, Gross MarginsPLX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 1K

More info and screens

5

2. Health

2.1 Basic Checks

PLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
PLX has more shares outstanding than it did 1 year ago.
PLX has more shares outstanding than it did 5 years ago.
PLX has a better debt/assets ratio than last year.
PLX Yearly Shares OutstandingPLX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
PLX Yearly Total Debt VS Total AssetsPLX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -4.40, we must say that PLX is in the distress zone and has some risk of bankruptcy.
PLX has a Altman-Z score (-4.40) which is in line with its industry peers.
PLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z -4.4
ROIC/WACCN/A
WACC9.86%
PLX Yearly LT Debt VS Equity VS FCFPLX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M

2.3 Liquidity

A Current Ratio of 1.98 indicates that PLX should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.98, PLX is doing worse than 76.38% of the companies in the same industry.
PLX has a Quick Ratio of 1.27. This is a normal value and indicates that PLX is financially healthy and should not expect problems in meeting its short term obligations.
PLX has a worse Quick ratio (1.27) than 83.30% of its industry peers.
Industry RankSector Rank
Current Ratio 1.98
Quick Ratio 1.27
PLX Yearly Current Assets VS Current LiabilitesPLX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for PLX have decreased strongly by -360.00% in the last year.
PLX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -28.24%.
PLX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.85% yearly.
EPS 1Y (TTM)-360%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%175%
Revenue 1Y (TTM)-28.24%
Revenue growth 3Y1.36%
Revenue growth 5Y13.85%
Sales Q2Q%73.6%

3.2 Future

Based on estimates for the next years, PLX will show a very strong growth in Earnings Per Share. The EPS will grow by 156.97% on average per year.
The Revenue is expected to grow by 29.99% on average over the next years. This is a very strong growth
EPS Next Y-69.7%
EPS Next 2Y152.25%
EPS Next 3Y156.97%
EPS Next 5YN/A
Revenue Next Year-13.69%
Revenue Next 2Y18.92%
Revenue Next 3Y29.99%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PLX Yearly Revenue VS EstimatesPLX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
PLX Yearly EPS VS EstimatesPLX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 2 -2 4 6

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PLX. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 7.51, which indicates a rather cheap valuation of PLX.
98.58% of the companies in the same industry are more expensive than PLX, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.68, PLX is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 7.51
PLX Price Earnings VS Forward Price EarningsPLX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

95.38% of the companies in the same industry are more expensive than PLX, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 24.54
EV/EBITDA N/A
PLX Per share dataPLX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6

4.3 Compensation for Growth

PLX's earnings are expected to grow with 156.97% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y152.25%
EPS Next 3Y156.97%

More info and screens

0

5. Dividend

5.1 Amount

PLX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROTALIX BIOTHERAPEUTICS INC

NYSEARCA:PLX (2/21/2025, 8:04:01 PM)

After market: 2.39 0 (0%)

2.39

-0.04 (-1.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)03-13 2025-03-13/amc
Inst Owners6.74%
Inst Owner Change-96.69%
Ins Owners7.79%
Ins Owner Change0%
Market Cap175.98M
Analysts80
Price Target14.79 (518.83%)
Short Float %6.83%
Short Ratio7.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-137.13%
Min EPS beat(2)-248.51%
Max EPS beat(2)-25.74%
EPS beat(4)0
Avg EPS beat(4)-150.58%
Min EPS beat(4)-248.51%
Max EPS beat(4)-25.74%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)8.05%
Min Revenue beat(2)6.72%
Max Revenue beat(2)9.37%
Revenue beat(4)3
Avg Revenue beat(4)8.86%
Min Revenue beat(4)-59.64%
Max Revenue beat(4)79%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.57%
PT rev (3m)3.57%
EPS NQ rev (1m)-12.5%
EPS NQ rev (3m)-12.5%
EPS NY rev (1m)-25%
EPS NY rev (3m)-25%
Revenue NQ rev (1m)3.01%
Revenue NQ rev (3m)3.01%
Revenue NY rev (1m)1.04%
Revenue NY rev (3m)0.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 7.51
P/S 3.85
P/FCF 24.54
P/OCF 21.26
P/B 5.43
P/tB 5.43
EV/EBITDA N/A
EPS(TTM)-0.13
EYN/A
EPS(NY)0.32
Fwd EY13.31%
FCF(TTM)0.1
FCFY4.07%
OCF(TTM)0.11
OCFY4.7%
SpS0.62
BVpS0.44
TBVpS0.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.6%
ROE -29.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 35.86%
FCFM 15.7%
ROA(3y)-18.11%
ROA(5y)-20.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y54.76%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.76%
GM growth 5Y-2.28%
F-Score5
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 86.28%
Cap/Sales 2.42%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.98
Quick Ratio 1.27
Altman-Z -4.4
F-Score5
WACC9.86%
ROIC/WACCN/A
Cap/Depr(3y)94.88%
Cap/Depr(5y)74.86%
Cap/Sales(3y)2.29%
Cap/Sales(5y)1.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-360%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%175%
EPS Next Y-69.7%
EPS Next 2Y152.25%
EPS Next 3Y156.97%
EPS Next 5YN/A
Revenue 1Y (TTM)-28.24%
Revenue growth 3Y1.36%
Revenue growth 5Y13.85%
Sales Q2Q%73.6%
Revenue Next Year-13.69%
Revenue Next 2Y18.92%
Revenue Next 3Y29.99%
Revenue Next 5YN/A
EBIT growth 1Y-165.62%
EBIT growth 3Y56.86%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y125.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y130.12%
OCF growth 3YN/A
OCF growth 5YN/A